Purpose Intraperitoneal (IP) cisplatin and intravenous (IV) or IP paclitaxel constitute a standard therapy for optimally debulked ovarian cancer. Bevacizumab prolongs progression-free survival (PFS) ...

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Discover new treatments like ART-123 advancing toward approval to prevent long-term nerve damage caused by ...

Austin-based PanTher Therapeutics, a clinical-stage company redefining cancer treatment with therapeutics administered continuously and exclusively at the tumour site, announced that the first patient ...

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide ( ) with these numbers expected to grow. The American Cancer Society ...

First trial participant treated with PTM-101, an investigational thin film formulation of paclitaxel placed directly over the tumor for continuous localized ...

Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, ...

Objectives To analyse patient profiles, transportation patterns and time delays in ischaemic time and door-to-balloon (DTB) time and evaluate the effect of these delays on in-hospital mortality among ...